Brooke McCormick


KFF Webinar Explores Insurance Coverage of Opill

Laurie Sobel, associate director for women’s health policy at KFF, moderated a panel discussion about the challenges associated with providing insurance coverage for the first FDA-approved oral contraceptive, Opill.

Tony Hagen


Hemophilia Groups Protest BCBS of Tennessee Formulary Exclusions

The patient groups say the insurer is cutting off access to important medications. The Tennessee Blues plans say many of the drugs that it excluded from coverage have zero utilization.

Susan Ladika


Drugs and Older Age: An Increasingly Deadly Combination

Two reports show that drug-related deaths are skyrocketing among people 65 years and older.

Peter Wehrwein


FDA Approves Rezdiffra, First Drug for NASH

Madrigal Pharmaceuticals is pricing Rezdiffra (resmetirom) at wholesale acquisition price of $47,400 per year.

Formulary Watch


FDA Sets Date for Zanidatamab in Bile Duct Cancer

Zanidatamab is bispecific antibody that targets HER2 in patients with metastatic biliary tract cancer. The FDA has set an action date of Nov. 29, 2024.

Richard Payerchin


California Sues Drug Makers, PBMs Over Rising Prices for Insulin

Lawsuit accuses the companies of using unlawful, unfair, and deceptive practices.

Timothy P. Gauthier, PharmD, BCPS


Antimicrobial stewardship programs-A review for the formulary decision-maker

Antimicrobial stewardship programs are being implemented in a variety of settings to assist with the challenges associated with the management of infectious diseases. Here's a review of ASPs from the perspective of a formulary decision-maker.

John Parkinson


FDA Approves GSK's BLA for 5-in-1 Meningococcal Vaccine

The vaccine combines the antigenic components of its two meningococcal vaccines: Bexsero and Menveo. The action date is Feb. 14, 2025.

Rosanna Sutherby, Pharm.D.


GlaxoSmithKline Halts RSV Vaccine Trials in Pregnant Women

The setback for GlaxoSmithKline comes amid a multicompany race to develop a vaccine against respiratory syncytial virus infections.

Keith Loria


Up, Up and Not Going Away: Cancer Drug Prices

Escalating costs are hitting patients hard. CMS price negotiation and the $2,000 cap on Part D out-of-pocket expenses should benefit many patients with Medicare coverage.

Laura Joszt, MA


Analysis Finds Biosimilars Can Reduce Total Cost of Care

A simulation study estimated the impact of biosimilar substitution on total cost of care and provider financial performance in the final performance period of the Oncology Care Model.

Jennifer Gershman, Pharm.D., CPh


Second mRNA COVID-19 Vaccine in Primary Series Can Be Extended to 8 Weeks for Some Individuals

This guidance discusses that individuals 12 years and older can receive the second dose of the Pfizer-BioNTech vaccine 3-8 weeks after the first. Additionally, the interval for those 18 years and older for Moderna is 4-8 weeks.

Patricia Weiser, Pharm.D.


FDA Warns About Malignancies from CAR-T Therapies

The FDA orders new warnings for CAR-T cell therapies due to reports of T-cell malignancies, including fatal cases, applying to BCMA- and CD19-directed genetically modified autologous T-cell immunotherapies.

Joshua Fitch


Spending on Children’s Mental Health Conditions Increases, Study Finds

In 2021, pediatric mental health conditions were associated with $31 billion in child spending and $59 billion in household spending, which made up 46.6% of all pediatric medical spending that year.

Denise Myshko


Global Spending on Cancer Drugs to Increase to $409 Billion

In the United States, spending on oncology therapies rose to $99 billion in 2023, and is expected to grow to nearly $180 billion in 2028, finds a recent report by IQVIA Institute for Human Data Science.

Jared Kaltwasser


Study: One-Third of ACOs Use Digital Health Tools for Opioid Use Disorder

Accountable care organizations (ACOs) use digital health to complement traditional resources.

Don Creighton


Inflation Reduction Act and the Impact on Pharmaceutical Pricing and Investment Decisions

The reference to “maximum fair price” in the act bodes poorly for manufacturers and suggests more of a take-it-or-leave-it situation rather than a negotiation where clinical evidence would be the prevailing factor in determining price.

Celeste Krewson


Long-term Study Shows Gardasil 9 Effective Against HPV-Related Cancers

In a 10-year, follow-up study in patients vaccinated with Gardasil 9, no cases of HPV-related cancers or genital warts were seen.

Nathan R. Unger, PharmD


Antimicrobial stewardship programs-A review for the formulary decision-maker

Antimicrobial stewardship programs are being implemented in a variety of settings to assist with the challenges associated with the management of infectious diseases. Here's a review of ASPs from the perspective of a formulary decision-maker.

Jaime Rosenberg


Study: Medicaid Coverage Uneven for Gene Therapies

Recent study finds that Medicaid coverage for some of the first gene and cell therapies was at times delayed and not consistent with federal requirements.

Skylar Jeremias


FDA Approves Stelara Biosimilar, Selarsdi

Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.

Jeffrey Bendix


Report: Medical Costs to Rise 7% Next Year

The increase is expected to be somewhat offset by the impact of biosimilars coming to market and more care being provided in outpatient settings.

Logan Lutton


Survey: Many Support Medicare Coverage of Weight Loss Drugs

Although most older adults support Medicare coverage of medications for weight loss drugs, only one in three favor paying more in premiums for this coverage, finds University of Michigan survey.

Lauren Biscaldi


FDA Approves Chikungunya Virus Vaccine

Ixchiq was approved through the FDA Accelerated Approval pathway.

Justina Petrullo


Review: Patients Can Safely Switch to Biosimilars

Researchers in this review suggest clinical trials of biosimilars include switching studies to assess the pharmacokinetics of the biosimilar candidate.

Briana Contreras


Amylyx Pulls ALS Treatment Off Market With a Few Thousand Still on Treatment as of Late '23

Approved in late September 2022, Relyvrio will no longer be available for new amyotrophic lateral sclerosis (ALS) patients.

Christine Blank


Pfizer Tornado Plant Damage Not Affecting Penicillin Supply

The supply of fentanyl, epinephrine injection, and heparin, however, have been impacted by the July 19 tornado at Pfizer's North Carolina facility.

Tracey Walker


Overactive bladder drug not linked to CV events

Patients with overactive bladder taking this OAB drug did not experience an excess risk of CV events compared with other treatments.

© 2024 MJH Life Sciences

All rights reserved.